Suxinutin (Ethosuximide) Oral Solution
Succinimide anticonvulsant for absence seizures – a liquid formulation suitable for children and adults
Quick Facts About Suxinutin
Key Takeaways About Suxinutin
- First-line for absence seizures: Suxinutin is the internationally recommended first-line treatment for childhood absence epilepsy, supported by the landmark SANAD and Glauser trials and endorsed by the International League Against Epilepsy (ILAE)
- Liquid form allows precise paediatric dosing: The 50 mg/mL oral solution makes it possible to accurately titrate doses by body weight in young children and in patients who cannot swallow solid forms
- Regular blood monitoring essential: Complete blood counts must be checked monthly during the first year and every six months thereafter to detect rare but serious bone marrow suppression
- Gradual dose titration: Treatment starts at a low dose and is slowly increased every 4–7 days to minimise side effects, with a typical maintenance dose of 20–30 mg/kg/day in children and 1,000–1,500 mg/day in adults
- Never stop abruptly: Sudden discontinuation can trigger rebound seizures or absence status epilepticus – the dose must always be tapered gradually under medical supervision
What Is Suxinutin and What Is It Used For?
Suxinutin is a prescription anticonvulsant oral solution used primarily to treat absence seizures (petit mal epilepsy). It contains 50 mg/mL of ethosuximide, a succinimide antiepileptic drug that works by blocking low-threshold T-type calcium channels in the thalamus, preventing the abnormal electrical discharges that cause absence seizures. It is approved for use in adults, the elderly, and children from early childhood onwards.
Ethosuximide, the active ingredient in Suxinutin, was introduced for clinical use in 1958 and has since become one of the most important medications in the treatment of absence epilepsy. It remains the first-line treatment recommended by the International League Against Epilepsy (ILAE) for childhood absence epilepsy, a position reinforced by the landmark Standard and New Antiepileptic Drugs (SANAD) trial, the Glauser et al. multicentre trial published in the New England Journal of Medicine, and multiple subsequent Cochrane systematic reviews. The World Health Organization includes ethosuximide on its Model List of Essential Medicines, recognising its critical role in epilepsy management worldwide.
Absence seizures are a specific type of generalised epileptic seizure characterised by brief episodes of staring and unresponsiveness, typically lasting 5 to 30 seconds. During an absence seizure the person appears to "blank out" and may show subtle signs such as eye blinking, lip smacking or automatisms of the hands. These seizures are most common in children between ages 4 and 14, and can occur dozens or even hundreds of times per day, significantly affecting school performance, social development and quality of life. The electroencephalogram (EEG) during an absence seizure shows a characteristic 3 Hz (three per second) generalised spike-and-wave pattern, which is highly specific for this seizure type.
Suxinutin is formulated as a sweetened oral solution containing 50 milligrams of ethosuximide per millilitre. Because absence epilepsy frequently begins in early childhood – often before a child can reliably swallow capsules or tablets – the liquid formulation has important advantages. Doses can be measured precisely using an oral syringe or measuring cup, allowing paediatric doses to be titrated by body weight and adjusted in small increments. The liquid form also improves adherence in older patients who experience difficulty swallowing, and makes administration through an enteral feeding tube possible when clinically required.
Approved Indications
- Absence seizures (petit mal epilepsy): The primary and most well-established indication for ethosuximide. It is effective for both typical and atypical absence seizures and is considered the treatment of choice for childhood absence epilepsy when no generalised tonic-clonic seizures are present
- Myoclonic and myoclonic-atonic seizures in adolescents: Ethosuximide may be used as a second-line treatment for these seizure types when other antiepileptic drugs have proven ineffective or are not tolerated. Myoclonic seizures involve sudden, brief involuntary muscle jerks, while myoclonic-atonic seizures combine a brief jerk followed by a sudden loss of muscle tone
- Juvenile absence epilepsy and other generalised epilepsies: In selected cases, ethosuximide may be combined with a broad-spectrum antiepileptic drug to provide coverage for multiple seizure types in the same patient
How Does Suxinutin Work?
Suxinutin exerts its anticonvulsant effect primarily by blocking low-threshold T-type calcium channels (specifically the Cav3.2 subtype, also known as α1H) in thalamic relay neurons. These T-type calcium channels play a critical role in generating the rhythmic thalamocortical oscillations that underlie the 3 Hz spike-and-wave discharges characteristic of absence seizures. By reducing T-type calcium currents, ethosuximide disrupts the synchronised neuronal firing pattern that produces the clinical manifestation of an absence seizure.
The thalamus acts as a pacemaker for absence seizures, with thalamic relay neurons switching between two firing modes: a tonic mode during normal wakefulness and a burst-firing mode during sleep or absence seizures. T-type calcium channels are essential for burst firing, and by inhibiting these channels ethosuximide prevents the transition to the burst-firing mode that generates absence seizures. This highly specific mechanism of action explains why ethosuximide is particularly effective for absence seizures but is not useful for other seizure types such as focal or generalised tonic-clonic seizures.
Additional mechanisms may also contribute to the therapeutic effect. Some evidence suggests that ethosuximide reduces certain persistent sodium currents and modulates calcium-activated potassium channels in thalamic neurons. These complementary actions further reduce thalamic neuronal excitability and reinforce its antiabsence efficacy. Because the molecular target is expressed almost exclusively within the thalamocortical circuit, ethosuximide has a comparatively narrow spectrum of action – a property that contributes to its favourable cognitive and behavioural profile relative to some broader-spectrum antiepileptic drugs.
Pharmacokinetically, ethosuximide is almost completely absorbed after oral administration, with peak plasma concentrations reached within 1 to 4 hours. Because Suxinutin is a solution, absorption is typically rapid and predictable. The drug is not significantly protein-bound, is distributed throughout body water and is metabolised primarily in the liver by the CYP3A4 and CYP2E1 enzyme systems. Its long elimination half-life (approximately 40–60 hours in adults and 30–40 hours in children) supports convenient once- or twice-daily dosing once steady state has been reached.
What Should You Know Before Taking Suxinutin?
Before starting Suxinutin, your doctor must evaluate your blood counts and liver function. The medication is contraindicated in patients allergic to ethosuximide or other succinimides and in patients with porphyria. Special caution is needed in patients with a history of psychiatric disorders, liver disease, kidney disease, or hereditary fructose intolerance, and alcohol must be avoided completely during treatment.
Contraindications
Suxinutin must not be taken in the following situations:
- Allergy to ethosuximide or succinimides: If you have a known hypersensitivity to ethosuximide, any other succinimide anticonvulsant (such as methsuximide or phensuximide), or any of the excipients used in the oral solution (listed in the composition section below)
- Porphyria: Ethosuximide is contraindicated in patients with acute intermittent porphyria or other forms of hepatic porphyria, as it may precipitate a porphyric crisis. Porphyrias are a group of rare inherited metabolic disorders that affect the production of haem, a component of haemoglobin
- Hereditary fructose intolerance: Because the oral solution may contain sorbitol or fructose-derived excipients, it should not be used in patients with hereditary fructose intolerance unless the specific product labelling confirms the formulation is free of these sugars
Warnings and Precautions
Treatment with Suxinutin requires careful medical supervision. The following precautions should be discussed with your doctor before and during treatment:
Suxinutin can cause serious blood disorders including agranulocytosis (loss of white blood cells that fight infection), aplastic anaemia (failure of the bone marrow to produce blood cells), and pancytopenia (deficiency of all types of blood cells). These conditions can be life-threatening. Your blood counts will be checked regularly – monthly during the first year and every six months thereafter. Seek immediate medical attention if you develop fever, sore throat, mouth ulcers, unusual bruising or bleeding, or persistent fatigue.
Movement disorders (dyskinesia): In rare cases, movement disorders may develop within the first 12 hours of starting treatment. If you experience involuntary movements, stop taking the medication and contact your doctor immediately. Your doctor may administer intravenous diphenhydramine as an antidote in severe cases. These reactions typically resolve once the drug is discontinued and the bulk of it has been eliminated.
Psychiatric effects: Psychological side effects including anxiety, depression, hallucinations, and paranoia may occur, particularly in patients with a pre-existing history of psychiatric disorders. Your doctor will take special care when prescribing ethosuximide if you have had previous mental health conditions, and any new or worsening psychiatric symptoms should be reported promptly. In rare cases a paradoxical increase in seizure frequency has also been reported.
Suicidal thoughts: A small number of patients treated with antiepileptic medications, including ethosuximide, have experienced thoughts of self-harm or suicide. If you develop such thoughts at any time during treatment, contact your doctor immediately or seek emergency medical attention. This risk applies to all antiepileptic drugs and was identified through large-scale meta-analyses conducted by regulatory agencies such as the U.S. FDA and the European Medicines Agency.
Serious and potentially life-threatening skin reactions have been reported with ethosuximide, including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS). Stop taking Suxinutin and seek immediate medical care if you develop target-like or round reddish spots on the trunk, skin blistering or peeling, sores in the mouth, throat, nose or eyes, widespread rash with fever, or swollen lymph nodes.
Liver function monitoring: Your liver enzymes will be monitored regularly throughout treatment. Ethosuximide is metabolised by the liver, and hepatic impairment may affect drug levels and increase the risk of toxicity. Report any symptoms of liver problems – such as yellowing of the skin or eyes (jaundice), dark urine, pale stools, or persistent nausea – to your doctor.
Renal function: Although most ethosuximide is metabolised in the liver, about 20% of a dose is excreted unchanged in the urine. In patients with impaired kidney function, or in the elderly, plasma concentrations may rise unexpectedly. Periodic urinalysis is generally recommended during long-term therapy.
Lupus erythematosus: In rare cases, ethosuximide has been associated with the development of systemic lupus erythematosus (SLE) or a lupus-like syndrome. Symptoms may include joint pain, skin rash (particularly a butterfly-shaped rash on the face), fever and fatigue. Any such symptoms should be reported to your doctor.
Combination Therapy
Absence seizures are frequently associated with generalised tonic-clonic seizures, particularly in juvenile absence epilepsy and juvenile myoclonic epilepsy. Because ethosuximide is not effective against tonic-clonic seizures, your doctor may combine Suxinutin with another antiepileptic drug such as sodium valproate, lamotrigine or levetiracetam to provide adequate protection against both seizure types. In childhood absence epilepsy without concurrent tonic-clonic seizures, ethosuximide monotherapy is usually sufficient and is preferred because it has the most favourable cognitive and behavioural profile of the three first-line options.
How Does Suxinutin Interact with Other Drugs?
Suxinutin interacts with several other medications, particularly other antiepileptic drugs. Carbamazepine, phenobarbital and phenytoin may reduce ethosuximide levels through enzyme induction, while valproate and isoniazid may increase them. Sedative medications and alcohol may have enhanced central nervous system effects when combined with Suxinutin. Always inform your doctor and pharmacist about every medication, herbal remedy and supplement you are taking.
The following drug interactions are clinically significant and should be discussed with your prescribing physician before starting Suxinutin and whenever another medication is added or stopped:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Carbamazepine | May decrease ethosuximide plasma levels through hepatic enzyme induction | Monitor ethosuximide levels; dose increase may be required |
| Valproate (Valproic acid) | May increase ethosuximide plasma levels by inhibiting its metabolism | Monitor for increased side effects; a dose reduction may be necessary |
| Phenytoin | Variable effects: ethosuximide may raise phenytoin levels; phenytoin may lower ethosuximide levels | Monitor plasma levels of both drugs when used together |
| Phenobarbital / Primidone | May decrease ethosuximide levels through hepatic enzyme induction | Often combined intentionally for seizure control; monitor levels |
| Isoniazid | May inhibit ethosuximide metabolism and raise plasma levels | Monitor for signs of toxicity; a dose reduction may be necessary |
| Sedatives / Hypnotics / Opioids | Mutual enhancement of sedative and sleep-inducing effects | Use caution; combination may increase drowsiness and impair alertness |
| Alcohol | Unpredictable alteration and enhancement of ethosuximide effects; may lower seizure threshold | Alcohol must be avoided completely during treatment |
If you are taking other antiepileptic drugs alongside Suxinutin, your doctor may need to monitor plasma drug levels more frequently to ensure optimal dosing. The complex pharmacokinetic interactions between antiepileptic drugs make therapeutic drug monitoring an essential part of combination therapy. Herbal products such as St John's wort (Hypericum perforatum) are also known to induce hepatic enzymes and should be avoided unless specifically approved by your specialist.
Food and Drink
Suxinutin oral solution should be taken during or after a meal with half a glass of water or other non-alcoholic liquid. Taking the medication with food helps to reduce gastrointestinal side effects such as nausea, vomiting and stomach pain, without significantly altering absorption. Alcohol must be completely avoided during treatment, including foods and beverages that contain alcohol, as it can alter and enhance the effects of ethosuximide in unpredictable ways and may also lower the seizure threshold.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you might be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking Suxinutin. Treatment decisions in pregnancy should balance the risk of uncontrolled seizures – which can be dangerous to both mother and child – against the potential risk from the medication itself.
Pregnancy: If you are of childbearing age, your doctor should discuss the necessity of planning and monitoring any potential pregnancy before starting treatment with ethosuximide. While no specific malformations have been conclusively attributed to ethosuximide monotherapy, the overall risk of birth defects is generally higher for women taking antiepileptic drugs compared with the general population. The most commonly reported malformations associated with antiepileptic drugs in general include cleft lip, cardiovascular malformations, and neural tube defects (spina bifida). This risk is further increased when multiple antiepileptic drugs are used simultaneously, and combination therapy should therefore be avoided during pregnancy whenever possible.
The lowest effective dose that maintains seizure control should be used, particularly between days 20 and 40 of pregnancy (the critical period for organ development). Ethosuximide blood levels should be monitored regularly during pregnancy because changes in plasma volume and metabolism can alter drug concentrations. Folic acid supplementation (typically 4–5 mg daily) is recommended for women who are planning pregnancy or who are pregnant while taking any antiepileptic drug. To prevent vitamin K1 deficiency and associated bleeding in the newborn, vitamin K1 supplementation is advised during the final month of pregnancy.
Do not stop taking Suxinutin without first consulting your doctor, as uncontrolled seizures – and in particular prolonged convulsive seizures – can pose serious risks to both the mother and the unborn child.
Breastfeeding: Ethosuximide passes into breast milk in significant quantities, achieving concentrations similar to those in maternal plasma. Breastfeeding is not recommended during treatment with Suxinutin because of the potential risk of adverse effects in the nursing infant, including sedation and poor feeding.
Fertility: The effects of ethosuximide on human fertility have not been systematically studied. Discuss any fertility concerns with your healthcare provider, and inform your doctor promptly if pregnancy is planned or suspected.
Driving and Operating Machinery
Suxinutin may impair your reaction time and cognitive function, particularly during the initial adjustment phase of treatment and after dose increases. You should not drive motor vehicles, operate dangerous power tools, or work at heights or without a secure grip during periods when side effects such as drowsiness, dizziness or impaired concentration are present. You are personally responsible for assessing whether you are fit to drive or perform tasks that require alertness. Discuss this with your doctor or pharmacist if you are uncertain, and be aware that local laws may impose restrictions on driving with uncontrolled epilepsy.
What Is the Correct Dosage of Suxinutin?
For adults and children over 6 years, the recommended starting dose is 250–500 mg daily (5–10 mL of the 50 mg/mL oral solution). For children aged 3–6 years, treatment usually starts at 10–15 mg/kg/day. The dose is gradually increased every 4–7 days until seizure control is achieved. The typical maintenance dose is 20–30 mg/kg/day in children and 1,000–1,500 mg/day in adults, divided into two daily doses.
Always take Suxinutin exactly as prescribed by your doctor. An epilepsy specialist will determine the optimal dose based on individual response, seizure frequency, body weight and plasma drug levels. The therapeutic plasma concentration range for ethosuximide is generally considered to be 40–100 mcg/mL (283–708 µmol/L), although clinical response is the most important guide. The total daily dose is normally split into two intakes, typically morning and evening with meals, to minimise gastrointestinal side effects.
Suxinutin contains 50 mg of ethosuximide per millilitre. A 250 mg dose therefore corresponds to 5 mL, and a 500 mg dose corresponds to 10 mL. Always use the oral syringe or measuring cup provided with the medicine – household teaspoons and tablespoons are inaccurate and may lead to under- or overdosing. Rinse the syringe with water after each use and allow it to air-dry.
Adults and Elderly
Adult Dosing Schedule
Starting dose: 500 mg per day (10 mL), divided into two doses with meals
Dose titration: Increase by 250 mg (5 mL) every 4–7 days based on response and tolerability
Maintenance dose: 1,000–1,500 mg per day (20–30 mL), divided into two doses
Maximum dose: 2,000 mg per day (40 mL) in exceptional cases, divided into several doses
Children (Over 6 Years)
Paediatric Dosing Schedule (6 Years and Above)
Starting dose: 250–500 mg per day (5–10 mL), divided into two doses
Dose titration: Increase by 250 mg (5 mL) every 4–7 days based on the child's tolerance
Maintenance dose: 20–30 mg/kg/day, typically 750–1,500 mg per day, divided into two doses
Maximum dose: 40 mg/kg/day or 2,000 mg per day, whichever is lower
Children (3 to 6 Years)
Paediatric Dosing Schedule (3–6 Years)
Starting dose: 10–15 mg/kg/day, typically 250 mg per day (5 mL), as a single dose or divided into two
Dose titration: Increase slowly (every 4–7 days) based on seizure response and tolerability
Maintenance dose: 20–30 mg/kg/day, individualised according to plasma level and clinical effect
Note: The oral solution is particularly suitable for this age group because doses can be calculated precisely by body weight
Renal Impairment and Hemodialysis
Dosing in Kidney Disease
Ethosuximide is partly eliminated unchanged in the urine. In patients with moderate to severe renal impairment, dose adjustments may be needed and plasma monitoring is recommended. Ethosuximide is substantially removed during haemodialysis – approximately 39–52% of the administered dose is eliminated during a four-hour session. Hemodialysis patients therefore usually require a supplemental dose after each session. The treating nephrologist and neurologist should coordinate dosing decisions.
| Patient Group | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Adults | 500 mg/day (10 mL) | 1,000–1,500 mg/day | 2,000 mg/day |
| Elderly | 250–500 mg/day | 1,000–1,500 mg/day | 2,000 mg/day |
| Children (>6 years) | 250–500 mg/day | 20–30 mg/kg/day | 40 mg/kg/day or 2,000 mg/day |
| Children (3–6 years) | 10–15 mg/kg/day | 20–30 mg/kg/day | 40 mg/kg/day |
| Hemodialysis | Individualised | Supplemental dose post-dialysis | Based on plasma levels |
Duration of Treatment
Epilepsy treatment with Suxinutin is generally a long-term therapy. The size of your dose, how it should be distributed throughout the day, and when and how you should discontinue treatment will be determined by a specialist experienced in epilepsy management. Regular follow-up appointments are essential to assess treatment effectiveness, monitor for side effects, and adjust the dose as the patient grows or as circumstances change.
If seizures have been well controlled for at least two years, your doctor may consider gradually tapering the dose to determine whether treatment can be discontinued. This process should always be done slowly and under close medical supervision, as abrupt discontinuation can trigger rebound seizures. In childhood absence epilepsy, many children eventually achieve lasting seizure freedom, but this outcome is not guaranteed and decisions about stopping treatment must be individualised.
Missed Dose
If you miss a dose, take it as soon as you remember unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your normal dosing schedule. Do not take a double dose to make up for a missed one. Missing a single dose usually does not cause symptoms, but remember that ethosuximide only controls your epilepsy effectively if taken regularly. If you frequently forget to take your medication, discuss this with your doctor or pharmacist, who can suggest strategies – such as alarms, pill organisers or linking doses to daily routines – to improve adherence.
Overdose
If you accidentally take a double dose, do not change your dosing schedule – continue taking Suxinutin as prescribed by your doctor. If you or someone else has taken a significantly excessive amount of the medication, contact your doctor, hospital emergency department, or the poison control centre immediately. Keep the medicine packaging with you so that medical staff know exactly what has been taken.
Symptoms of ethosuximide overdose may include:
- Excessive drowsiness, lethargy and slurred speech
- Nausea and vomiting
- Unsteady gait (ataxia) and incoordination
- Depressive states, anxiety or agitation
- Irritability (particularly in children)
- Respiratory depression (in severe cases)
- Coma (in very severe cases)
These symptoms may be worsened by alcohol or other substances that affect the central nervous system. There is no specific antidote for ethosuximide overdose; treatment is supportive and may include airway protection, gastric decontamination with activated charcoal if presented early, and monitoring of vital functions. Haemodialysis may be effective in removing ethosuximide from the body in severe overdoses.
What Are the Side Effects of Suxinutin?
The most common side effects of Suxinutin are gastrointestinal symptoms (nausea, vomiting, abdominal pain, hiccups), drowsiness, dizziness, headache, skin rash and hives. Serious but rare side effects include blood disorders (agranulocytosis, aplastic anaemia), severe skin reactions (Stevens-Johnson syndrome, DRESS) and psychiatric disturbances (psychosis, hallucinations). Most side effects are dose-dependent and can be minimised by gradual dose titration and administration with food.
Like all medicines, Suxinutin can cause side effects, although not everybody gets them. The following list includes side effects reported during clinical use and post-marketing surveillance. The risk of dose-dependent side effects can be reduced by starting treatment at a low dose, increasing gradually, and taking the medication with food.
Stop taking Suxinutin and seek immediate medical care if you experience any of the following serious side effects: psychosis (delusions, hallucinations), signs of severe blood disorders (persistent fever, severe sore throat, unusual bleeding or bruising), target-like skin spots or blistering (Stevens-Johnson syndrome), widespread rash with fever and swollen lymph nodes (DRESS), or suicidal thoughts.
Common to Very Common
- Nausea
- Vomiting
- Abdominal pain and cramping
- Hiccups
- Drowsiness
- Dizziness
- Headache
- Skin rash
- Urticaria (hives)
Uncommon
- Severe headache
- Lethargy (apathy, listlessness)
- Ataxia (movement disorders, unsteady gait)
- Difficulty concentrating
- Withdrawal syndrome on abrupt discontinuation
- Anxiety and irritability
- Sleep disturbances or insomnia
- Suicidal thoughts
- Psychosis (delusions, hallucinations)
- Decreased appetite and weight loss
- Diarrhoea
- Constipation
- Swollen gums or tongue
- Fatigue
Rare
- Agranulocytosis (loss of certain infection-fighting white blood cells)
- Thrombocytopenia (low platelet count, causing easy bruising and bleeding)
- Paranoia and hallucinations developing over days to weeks
- Lupus erythematosus (autoimmune skin and organ condition)
- Leukopenia (low white blood cell count)
- Eosinophilia (elevated eosinophil white blood cells)
- Myopia (nearsightedness)
- Blood in the urine (haematuria)
- Liver enzyme elevation
Not Known
- Stevens-Johnson syndrome (severe skin reaction with blistering and peeling)
- DRESS (drug reaction with eosinophilia and systemic symptoms)
- Aplastic anaemia (bone marrow failure to produce blood cells)
- Pancytopenia (deficiency of all blood cell types)
- Dyskinesia (involuntary movements, typically within the first 12 hours of treatment)
- Depression
- Restless agitation
- Paradoxical increase in seizure frequency
Long-term treatment with ethosuximide may, in some patients, affect cognitive performance, attention span or mood. This is particularly relevant for children and adolescents in educational settings, where subtle cognitive effects may influence academic performance. Regular assessments by your doctor and, where appropriate, neuropsychological evaluations can help identify and manage any cognitive impacts. Importantly, the Glauser et al. trial found that ethosuximide had the most favourable attentional profile among the three first-line options for childhood absence epilepsy (ethosuximide, valproate and lamotrigine).
Dose-dependent side effects can often be managed by adjusting the dose downward or by taking the medication with meals. Side effects that are independent of dose typically resolve when the medication is discontinued but may recur if treatment is restarted. Report any side effects to your doctor so they can assess the severity and determine the appropriate course of action. You can also report suspected side effects directly to your national pharmacovigilance authority, which helps to improve the safety profile of medicines for all patients.
How Should You Store Suxinutin?
Store Suxinutin below 25°C in the original bottle, tightly closed, and keep it out of the sight and reach of children. Do not freeze. Once opened, the oral solution is typically stable for the period specified in the product labelling (often 3–6 months). Do not use after the expiry date printed on the carton.
Proper storage is important to maintain the effectiveness and safety of Suxinutin oral solution. Follow these guidelines:
- Store below 25°C: Keep the bottle at room temperature, avoiding excessive heat and direct sunlight
- Do not freeze: Freezing may damage the integrity of the solution and its preservative system
- Keep the bottle tightly closed when not in use to prevent contamination and evaporation
- Keep out of the sight and reach of children at all times – the sweet taste of oral solutions can make them attractive to young children
- Do not use after the expiry date stated on the carton after "EXP." The expiry date refers to the last day of that month
- Observe the in-use shelf life: Once the bottle is opened, follow the in-use expiry stated in the patient information leaflet
- Do not dispose of medications in household waste or wastewater. Return unused medicines to your pharmacy for safe disposal, which protects the environment and prevents accidental ingestion
What Does Suxinutin Contain?
Each millilitre of Suxinutin oral solution contains 50 mg of ethosuximide as the active ingredient. The solution also contains excipients typically used in oral liquid formulations, such as sweeteners, flavouring agents, preservatives and purified water. Patients with hereditary fructose intolerance or sugar-related metabolic disorders should check the specific formulation with their pharmacist.
Active Ingredient
Each millilitre of Suxinutin oral solution contains 50 mg of ethosuximide (2-ethyl-2-methylsuccinimide), a member of the succinimide class of anticonvulsant drugs. Ethosuximide is a small, highly water-soluble molecule, which makes it well suited for formulation as a stable aqueous solution.
Inactive Ingredients (Excipients)
The other ingredients in Suxinutin oral solution are typically the following (exact composition may vary by national product and should be confirmed using the patient information leaflet supplied with your specific bottle):
- Sweeteners: Sucrose, saccharin sodium or sorbitol may be used to make the solution palatable
- Flavouring agents: Raspberry, strawberry or similar flavours to mask the taste of the active ingredient
- Preservatives: Methyl parahydroxybenzoate (E218) and/or propyl parahydroxybenzoate (E216), or potassium sorbate
- pH modifiers: Citric acid and sodium citrate to maintain a stable pH
- Solvent: Purified water
Considerations for Special Diets and Intolerances
Sugar content: If the formulation contains sucrose, patients with diabetes mellitus should be aware that each millilitre typically contributes a small quantity of carbohydrate. This is usually clinically insignificant at standard doses but may be relevant when larger daily volumes are prescribed.
Sorbitol and fructose intolerance: If sorbitol is used as a sweetener, patients with hereditary fructose intolerance should not take the medicine. Sorbitol can also have a mild laxative effect at higher volumes.
Parabens: Some formulations contain methyl- or propyl-parahydroxybenzoate, which may cause allergic reactions (possibly delayed) in sensitised individuals.
Gluten-free: Ethosuximide oral solutions are typically gluten-free, but patients with coeliac disease should confirm this with their pharmacist using the specific product labelling.
Appearance and Pack Sizes
Suxinutin oral solution is typically a clear, pale yellow, syrupy liquid with a sweet, fruit-flavoured taste. It is supplied in amber glass or high-density polyethylene bottles, usually containing 200 mL or 500 mL of solution. An oral dosing syringe or measuring cup is provided for accurate dose measurement. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Suxinutin
Both Suxinutin (ethosuximide) and sodium valproate are effective treatments for absence seizures. The landmark Glauser trial (NEJM 2010) and the SANAD trial showed that ethosuximide and valproate had similar 12-month seizure-freedom rates, but ethosuximide had fewer adverse effects on attention and cognitive function. Ethosuximide is therefore preferred as the first-line treatment for childhood absence epilepsy when absence seizures are the only seizure type. Valproate is preferred when both absence seizures and generalised tonic-clonic seizures are present, because ethosuximide is not effective against tonic-clonic seizures. The choice between the two should be made by your epilepsy specialist based on your specific seizure type, age, sex and other individual factors – particularly given valproate's known teratogenic risks in women of childbearing potential.
Suxinutin should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. While no specific birth defects have been conclusively linked to ethosuximide alone, all antiepileptic drugs carry a generally increased risk of congenital malformations. The lowest effective dose should be used, combination therapy should be avoided where possible, and folic acid supplementation is recommended. Plasma levels should be monitored regularly throughout pregnancy because changes in metabolism and volume of distribution can alter drug concentrations. Importantly, do not stop taking your medication without consulting your doctor, because uncontrolled absence or generalised seizures can also be dangerous for both mother and baby. Breastfeeding is not recommended during treatment with Suxinutin.
Suxinutin begins to have a therapeutic effect once steady-state blood levels are reached, which typically takes about 7–10 days with a consistent dose, given its long half-life of 40–60 hours in adults and 30–40 hours in children. However, since treatment starts at a low dose and is gradually increased, it may take several weeks to reach the optimal therapeutic dose. Your doctor will assess seizure frequency clinically and may order EEG recordings to confirm treatment response, since absence seizures can be subtle and easily missed. Do not increase the dose faster than recommended, as this increases the risk of gastrointestinal and central nervous system side effects.
Stopping Suxinutin suddenly can be dangerous. Abrupt discontinuation may trigger rebound absence seizures, which can be more frequent and severe than before treatment. In some cases it may even precipitate absence status epilepticus, a prolonged episode of continuous or rapidly recurring absence seizures that requires urgent medical care. If you and your doctor decide to discontinue treatment, the dose will be reduced gradually over weeks to months, often in small decrements. Never change your dose or stop taking the medication without medical guidance, even if you feel you no longer need it.
Yes. One of the main advantages of Suxinutin is that the oral solution formulation makes accurate paediatric dosing possible. Children from about 3 years of age can receive Suxinutin when clinically indicated, and the liquid form allows the dose to be calculated precisely by body weight (typically 20–30 mg/kg/day as a maintenance dose). Very young children (under 3 years) are only treated in specialist settings, usually by a paediatric neurologist, because absence epilepsy is rare at this age and other causes of staring episodes must be excluded. Your child's doctor will determine the most appropriate dose and monitoring schedule.
No. Alcohol must be completely avoided while taking Suxinutin. Alcohol can alter and enhance the effects of ethosuximide in unpredictable ways, potentially causing excessive drowsiness, impaired coordination and a lowered seizure threshold, which may increase the risk of both absence and convulsive seizures. This applies to all alcoholic beverages as well as foods containing significant amounts of alcohol. Even small amounts can interact with the medication. If you have questions about specific foods, beverages or over-the-counter products (such as alcohol-containing cough syrups), consult your pharmacist before use.
Always use the oral syringe or measuring cup provided with your Suxinutin bottle. Because Suxinutin contains 50 mg per mL, a 5 mL dose equals 250 mg and a 10 mL dose equals 500 mg. Draw up the prescribed volume from the bottle, administer the dose directly into the mouth (or mix it with a small amount of water or juice if preferred), and then rinse the syringe with water. Never use a kitchen teaspoon, because the volume varies and can result in a dose that is too high or too low. If you are unsure how to measure the dose, ask your pharmacist to demonstrate the technique.
References
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine. 2010;362(9):790-799.
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141-155.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Ethosuximide listed as an essential anticonvulsant medicine for children and adults.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. The Lancet. 2007;369(9566):1016-1026.
- Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Annals of Neurology. 1989;25(6):582-593.
- European Medicines Agency (EMA). Ethosuximide – Summary of Product Characteristics. European Union harmonised information, updated 2025.
- International League Against Epilepsy (ILAE). Operational classification of seizure types and updated classification of the epilepsies. Epilepsia. 2017;58(4):512-521 (with subsequent 2022 syndrome position papers).
- Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews. 2005;(4):CD003032.
- U.S. Food and Drug Administration (FDA). Drug Safety Communication: Suicidality and antiepileptic drugs. Updated 2023.
- British National Formulary (BNF) and BNF for Children. Ethosuximide monograph. Joint Formulary Committee. Updated 2025.
- Patsalos PN. Antiepileptic drug pharmacokinetics and therapeutic drug monitoring. Epileptic Disorders. 2019;21(S1):S13-S22.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in neurology, clinical pharmacology and paediatric epileptology. All content follows international clinical guidelines and is based on evidence level 1A (systematic reviews and meta-analyses of randomised controlled trials). We align our recommendations with WHO, EMA, FDA, NICE and ILAE positions, and we update content whenever significant new evidence becomes available.
All drug information is independently verified against official sources including EMA Summary of Product Characteristics (SmPC), FDA prescribing information, WHO essential medicines guidelines and BNF monographs. Content is updated whenever new safety information becomes available and is reviewed at least annually.
iMedic receives no funding from pharmaceutical companies. All content is editorially independent. Our editorial team has no financial relationships with any manufacturer of the medications described and declares no conflict of interest in producing this article.